Cocrystal Pharma, Inc.
Bothell, WA
- UEI
- UY8UDESGRJ17
- CAGE
- 7SGF5
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 19805 N Creek Pkwy #100, Bothell, WA 98011, USA
- Website
- cocrystalpharma.com
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $498,199 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of pan-influenza inhibitors targeting the PA endonuclease from the viral replication complex | National Institute of Allergy and Infectious Diseases (NIH) | $498,199 |
SBA capabilities narrative
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and clinical advancement of innovative antiviral therapeutics for serious and chronic viral diseases. The company employs a proprietary structure-based drug discovery platform supported by Nobel Prize-winning scientific expertise to design first- and best-in-class small-molecule antivirals that target highly conserved viral replication enzymes. This approach enables efficient identification, optimization, and development of broad-spectrum antiviral drug candidates. Cocrystal Pharma's pipeline includes clinical and preclinical programs addressing influenza, norovirus, coronaviruses including SARS-CoV-2, hepatitis C, and other high-priority viral pathogens. The company has successfully advanced multiple programs through Phase 1 and Phase 2 clinical trials and collaborates with government agencies and global pharmaceutical partners to address critical public health needs.
Quick answers
Is Cocrystal Pharma, Inc. registered in SAM.gov?
Yes. Cocrystal Pharma, Inc.'s SAM.gov registration is active through December 11, 2026.
How much has Cocrystal Pharma, Inc. received in federal contracts?
Federal contracts obligated $498,199 to Cocrystal Pharma, Inc. in fiscal year 2025.
What is Cocrystal Pharma, Inc.'s most recent federal award?
Cocrystal Pharma, Inc.'s most recent federal contract award is Development of pan-influenza inhibitors targeting the PA endonuclease from the viral replication complex (75N93025C00038), from National Institute of Allergy and Infectious Diseases (NIH), on September 29, 2025.
On GovTribe
See Cocrystal Pharma, Inc.'s full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors